Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - ...

Dr. Buchanan will helm Belharra’s research organization as the company progresses its lead immunology and oncology programs, advances activities with its pharma collaborators, and enriches its ...

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases ...

Liverpool: Liverpool manager Arne Slot said Accrington Stanley s trip to Anfield in the FA Cup third round on Saturday will ...

The official added that a local reporter had, without permission, filmed the construction work at National Stadium Karachi ...

Mamelodi Sundowns’ patchy form has been due to chopping and changing in the technical team. Now their last two CAF Champions ...

After 34 years the iconic Day of Champions has come to an end. After a new schedule for the 2025 British Grand Prix has been ...

Saim Ayub suffered an ankle injury while fielding during the first day of the second Test against South Africa in Cape Town ...